Ruxolitinib for CALR-positive Myelofibrosis: A Case Report and Literature Review

Ruxolitinib for CALR-positive Myelofibrosis: A Case Report and Literature Review

Bibliographic Details
Main Authors:	GUO Huimei, HUA Luoming, XUE Hua, WANG Jing, ZHAO Songying, ZHANG Jiangbo
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2018-08-01
Series:	Zhongliu Fangzhi Yanjiu
Online Access:	http://html.rhhz.net/ZLFZYJ/html/8578.2018.17.1621.htm

Similar Items

Ruxolitinib as an emerging treatment in myelofibrosis
by: Emanuel RM, et al.
Published: (2013-03-01)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017-02-01)

Pleomorphic circulating megakaryocytes in a case of CALR positive primary myelofibrosis in leukemic transformation
by: Habib Moshref Razavi
Published: (2021-11-01)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
by: Paola Guglielmelli, et al.
Published: (2023-01-01)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
by: Peng Y, et al.
Published: (2020-09-01)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
by: Simone Claudiani, et al.
Published: (2021-09-01)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
by: Timothy Devos, et al.
Published: (2022-01-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by: Bewersdorf JP, et al.
Published: (2019-12-01)

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report
by: Mahija Cheekati, et al.
Published: (2024-04-01)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
by: Lasse Kjær, et al.
Published: (2023-05-01)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
by: F. Palandri, et al.
Published: (2022-06-01)

A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis
by: Tim Kong, et al.
Published: (2024-03-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
by: Claire Harrison, et al.
Published: (2022-08-01)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
by: P. Harrington, et al.
Published: (2022-06-01)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
by: Francesca Palandri, et al.
Published: (2023-10-01)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
by: Vera Stoeva, et al.
Published: (2023-07-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
by: Arthur E. Frankel, et al.
Published: (2021-04-01)

Ruxolitinib Treatment During Myelofibrosis Leads to Cutaneous Mycobacterium marinum Infection: A Case Report
by: Chen X, et al.
Published: (2023-06-01)

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
by: J. Mei, et al.
Published: (2022-06-01)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
by: Natalia Korsakova, et al.
Published: (2023-08-01)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
by: C. Harrison, et al.
Published: (2022-06-01)

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
by: Novella Pugliese, et al.
Published: (2019-06-01)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
by: Francesca Palandri, et al.
Published: (2021-01-01)

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
by: Meltem Aylı, et al.
Published: (2015-05-01)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
by: C. Chen, et al.
Published: (2022-06-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
by: Z. Xu, et al.
Published: (2022-06-01)

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
by: Harrison, C, et al.
Published: (2016)

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
by: D. Cattaneo, et al.
Published: (2022-06-01)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
by: M. I. Montero
Published: (2022-06-01)

Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
by: Byung-Hyun Lee, et al.
Published: (2021-10-01)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
by: Li Huo, et al.
Published: (2023-01-01)

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
by: Tanja Belčič Mikič, et al.
Published: (2021-03-01)

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
by: Ayalew Tefferi, et al.
Published: (2024-03-01)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
by: P. Abraham, et al.
Published: (2022-06-01)

Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review
by: Rong Chen, et al.
Published: (2022-04-01)